Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 66 | 2024 | 4995 | 3.080 |
Why?
|
Glioma | 27 | 2024 | 2001 | 1.610 |
Why?
|
Radiosurgery | 18 | 2024 | 1369 | 1.400 |
Why?
|
Neurosurgical Procedures | 14 | 2021 | 638 | 1.310 |
Why?
|
Monitoring, Intraoperative | 8 | 2021 | 269 | 1.310 |
Why?
|
Magnetic Resonance Imaging | 39 | 2024 | 7959 | 1.210 |
Why?
|
Diffusion Magnetic Resonance Imaging | 6 | 2020 | 347 | 1.140 |
Why?
|
Spinal Cord Neoplasms | 6 | 2017 | 148 | 1.120 |
Why?
|
Laser Therapy | 11 | 2020 | 422 | 1.080 |
Why?
|
Meningeal Neoplasms | 7 | 2021 | 457 | 0.970 |
Why?
|
Temporal Lobe | 5 | 2016 | 196 | 0.920 |
Why?
|
Hyperthermia, Induced | 6 | 2020 | 516 | 0.770 |
Why?
|
Meningeal Carcinomatosis | 2 | 2017 | 31 | 0.720 |
Why?
|
Craniotomy | 10 | 2014 | 313 | 0.710 |
Why?
|
Magnetic Resonance Imaging, Interventional | 2 | 2017 | 106 | 0.670 |
Why?
|
Glioblastoma | 11 | 2020 | 1844 | 0.650 |
Why?
|
Neuronavigation | 6 | 2021 | 47 | 0.630 |
Why?
|
Extracorporeal Shockwave Therapy | 1 | 2017 | 6 | 0.610 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2010 | 203 | 0.590 |
Why?
|
Essential Tremor | 1 | 2017 | 87 | 0.550 |
Why?
|
Spinal Neoplasms | 7 | 2015 | 656 | 0.510 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 2733 | 0.490 |
Why?
|
Vision Disorders | 1 | 2017 | 242 | 0.490 |
Why?
|
Tertiary Care Centers | 1 | 2017 | 420 | 0.480 |
Why?
|
Middle Aged | 80 | 2024 | 89413 | 0.480 |
Why?
|
Neuropsychological Tests | 5 | 2016 | 1216 | 0.470 |
Why?
|
Ependymoma | 4 | 2017 | 262 | 0.470 |
Why?
|
Humans | 137 | 2024 | 270404 | 0.460 |
Why?
|
Immunoglobulin G | 2 | 2010 | 1059 | 0.460 |
Why?
|
Brain Stem Neoplasms | 2 | 2011 | 102 | 0.450 |
Why?
|
Adult | 69 | 2024 | 80581 | 0.440 |
Why?
|
Male | 83 | 2024 | 127406 | 0.410 |
Why?
|
Cancer Care Facilities | 1 | 2017 | 905 | 0.410 |
Why?
|
Tinea Pedis | 1 | 2011 | 4 | 0.410 |
Why?
|
Aged | 63 | 2024 | 72800 | 0.400 |
Why?
|
Brain | 11 | 2021 | 4187 | 0.390 |
Why?
|
Retrospective Studies | 46 | 2024 | 39440 | 0.390 |
Why?
|
Radiation Injuries | 7 | 2020 | 1449 | 0.390 |
Why?
|
Female | 81 | 2024 | 147053 | 0.380 |
Why?
|
Incidental Findings | 2 | 2024 | 285 | 0.370 |
Why?
|
Carcinoma | 2 | 2017 | 2600 | 0.370 |
Why?
|
Thiophenes | 1 | 2011 | 151 | 0.370 |
Why?
|
Off-Label Use | 1 | 2010 | 49 | 0.360 |
Why?
|
Cerebral Ventricle Neoplasms | 2 | 2023 | 81 | 0.360 |
Why?
|
Antibodies, Monoclonal | 3 | 2010 | 4442 | 0.350 |
Why?
|
Therapies, Investigational | 1 | 2010 | 63 | 0.350 |
Why?
|
Decompression, Surgical | 2 | 2003 | 148 | 0.350 |
Why?
|
Cognition Disorders | 1 | 2015 | 787 | 0.350 |
Why?
|
Melanoma | 7 | 2024 | 5444 | 0.340 |
Why?
|
Cerebellar Neoplasms | 3 | 2008 | 469 | 0.330 |
Why?
|
Treatment Outcome | 34 | 2024 | 34163 | 0.320 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2009 | 629 | 0.290 |
Why?
|
Skin Diseases | 1 | 2010 | 357 | 0.290 |
Why?
|
Herpesvirus Vaccines | 1 | 2006 | 3 | 0.290 |
Why?
|
Neuralgia, Postherpetic | 1 | 2006 | 8 | 0.290 |
Why?
|
Pigmentation Disorders | 1 | 2007 | 39 | 0.280 |
Why?
|
Sarcoma | 1 | 2017 | 1830 | 0.280 |
Why?
|
Herpesvirus 3, Human | 1 | 2006 | 45 | 0.280 |
Why?
|
CD11 Antigens | 1 | 2006 | 22 | 0.280 |
Why?
|
Benzoyl Peroxide | 1 | 2006 | 4 | 0.280 |
Why?
|
Medication Adherence | 1 | 2011 | 521 | 0.280 |
Why?
|
Pyramidal Tracts | 3 | 2014 | 57 | 0.270 |
Why?
|
Herpes Zoster | 1 | 2006 | 52 | 0.270 |
Why?
|
Neuroimaging | 3 | 2019 | 412 | 0.270 |
Why?
|
Acne Vulgaris | 1 | 2006 | 46 | 0.270 |
Why?
|
Surgery, Computer-Assisted | 4 | 2014 | 264 | 0.270 |
Why?
|
Dermatitis, Atopic | 1 | 2006 | 52 | 0.260 |
Why?
|
Melanocytes | 1 | 2007 | 231 | 0.260 |
Why?
|
Imidazoles | 1 | 2011 | 1028 | 0.260 |
Why?
|
Astrocytoma | 3 | 2013 | 328 | 0.260 |
Why?
|
Antifungal Agents | 1 | 2011 | 854 | 0.260 |
Why?
|
Onychomycosis | 1 | 2005 | 17 | 0.260 |
Why?
|
Foot Dermatoses | 1 | 2005 | 23 | 0.260 |
Why?
|
Speech | 2 | 2017 | 136 | 0.250 |
Why?
|
Young Adult | 27 | 2022 | 22096 | 0.250 |
Why?
|
Postoperative Complications | 5 | 2018 | 5817 | 0.250 |
Why?
|
Nails | 1 | 2005 | 36 | 0.250 |
Why?
|
Nicotinic Acids | 1 | 2005 | 35 | 0.250 |
Why?
|
Brain Mapping | 7 | 2017 | 661 | 0.250 |
Why?
|
Ganglioneuroma | 1 | 2004 | 41 | 0.250 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2004 | 38 | 0.240 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2010 | 1589 | 0.240 |
Why?
|
Cranial Fossa, Posterior | 2 | 2008 | 48 | 0.240 |
Why?
|
Neurothekeoma | 1 | 2003 | 10 | 0.230 |
Why?
|
Facial Dermatoses | 1 | 2003 | 23 | 0.230 |
Why?
|
Hyperpigmentation | 1 | 2003 | 32 | 0.230 |
Why?
|
Psoriasis | 1 | 2005 | 135 | 0.230 |
Why?
|
Kidney Neoplasms | 5 | 2022 | 3097 | 0.230 |
Why?
|
Thermography | 3 | 2014 | 59 | 0.230 |
Why?
|
Glioma, Subependymal | 1 | 2023 | 25 | 0.230 |
Why?
|
Meningioma | 2 | 2021 | 296 | 0.230 |
Why?
|
Combined Modality Therapy | 10 | 2023 | 9002 | 0.220 |
Why?
|
Forearm | 1 | 2003 | 72 | 0.220 |
Why?
|
Tacrolimus | 1 | 2005 | 345 | 0.220 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2003 | 21 | 0.220 |
Why?
|
Wakefulness | 3 | 2014 | 157 | 0.220 |
Why?
|
Supratentorial Neoplasms | 3 | 2013 | 79 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2023 | 10254 | 0.210 |
Why?
|
Memory Disorders | 2 | 2015 | 304 | 0.210 |
Why?
|
Diagnosis, Differential | 8 | 2017 | 4845 | 0.210 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2003 | 31 | 0.210 |
Why?
|
Encephalocele | 1 | 2003 | 56 | 0.210 |
Why?
|
Proton Therapy | 3 | 2019 | 1598 | 0.210 |
Why?
|
Skin Diseases, Viral | 1 | 2002 | 12 | 0.210 |
Why?
|
Herpesvirus 2, Human | 1 | 2002 | 20 | 0.210 |
Why?
|
Aminoquinolines | 1 | 2002 | 51 | 0.200 |
Why?
|
Adolescent | 28 | 2022 | 32250 | 0.200 |
Why?
|
Cerebellar Diseases | 1 | 2003 | 88 | 0.200 |
Why?
|
Fourth Ventricle | 2 | 2023 | 51 | 0.200 |
Why?
|
Acyclovir | 1 | 2002 | 78 | 0.200 |
Why?
|
Pinealoma | 1 | 2022 | 54 | 0.200 |
Why?
|
Follow-Up Studies | 13 | 2020 | 15182 | 0.200 |
Why?
|
Language | 2 | 2017 | 326 | 0.200 |
Why?
|
Valine | 1 | 2002 | 178 | 0.190 |
Why?
|
Emergencies | 1 | 2003 | 207 | 0.190 |
Why?
|
Cyclobutanes | 1 | 2021 | 37 | 0.190 |
Why?
|
Neurosurgeons | 1 | 2021 | 18 | 0.190 |
Why?
|
Herpes Simplex | 1 | 2002 | 95 | 0.190 |
Why?
|
Carboxylic Acids | 1 | 2021 | 57 | 0.190 |
Why?
|
Aged, 80 and over | 22 | 2024 | 30767 | 0.190 |
Why?
|
Functional Laterality | 3 | 2017 | 315 | 0.190 |
Why?
|
Carcinoma, Renal Cell | 3 | 2022 | 2387 | 0.180 |
Why?
|
Algorithms | 3 | 2020 | 3982 | 0.180 |
Why?
|
Surgical Equipment | 1 | 2019 | 17 | 0.180 |
Why?
|
Diffusion Tensor Imaging | 3 | 2014 | 311 | 0.180 |
Why?
|
Appointments and Schedules | 1 | 2020 | 97 | 0.180 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2019 | 611 | 0.170 |
Why?
|
Anti-HIV Agents | 1 | 2003 | 364 | 0.170 |
Why?
|
Benchmarking | 1 | 2021 | 289 | 0.170 |
Why?
|
Recombinant Fusion Proteins | 1 | 2005 | 1595 | 0.170 |
Why?
|
Viral Matrix Proteins | 1 | 2020 | 200 | 0.170 |
Why?
|
Mindfulness | 1 | 2020 | 58 | 0.170 |
Why?
|
Carcinoma, Basal Cell | 1 | 2002 | 278 | 0.160 |
Why?
|
Clinical Protocols | 1 | 2021 | 471 | 0.160 |
Why?
|
Survival Rate | 12 | 2019 | 12428 | 0.160 |
Why?
|
Meditation | 1 | 2020 | 76 | 0.160 |
Why?
|
Motor Cortex | 2 | 2010 | 117 | 0.160 |
Why?
|
Skull Fractures | 1 | 1999 | 48 | 0.160 |
Why?
|
Dura Mater | 1 | 1999 | 77 | 0.160 |
Why?
|
Skull Neoplasms | 1 | 1999 | 68 | 0.160 |
Why?
|
Diffusion of Innovation | 1 | 2019 | 159 | 0.160 |
Why?
|
Adalimumab | 2 | 2010 | 45 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 9 | 2023 | 7732 | 0.150 |
Why?
|
Etanercept | 2 | 2010 | 70 | 0.150 |
Why?
|
Surgical Oncology | 1 | 2020 | 192 | 0.150 |
Why?
|
Oligodendroglioma | 2 | 2016 | 107 | 0.150 |
Why?
|
Wernicke Area | 1 | 2017 | 11 | 0.150 |
Why?
|
Intraoperative Neurophysiological Monitoring | 2 | 2016 | 32 | 0.150 |
Why?
|
Catheter Ablation | 1 | 2023 | 649 | 0.150 |
Why?
|
Prospective Studies | 10 | 2023 | 13269 | 0.150 |
Why?
|
Radiotherapy Dosage | 4 | 2021 | 3967 | 0.150 |
Why?
|
Arnold-Chiari Malformation | 1 | 1998 | 55 | 0.150 |
Why?
|
Headache | 1 | 1998 | 165 | 0.150 |
Why?
|
Infliximab | 2 | 2010 | 140 | 0.150 |
Why?
|
Tertiary Healthcare | 1 | 2017 | 44 | 0.140 |
Why?
|
Ki-67 Antigen | 1 | 2019 | 681 | 0.140 |
Why?
|
Thoracic Vertebrae | 1 | 2017 | 193 | 0.140 |
Why?
|
Medical Oncology | 2 | 2021 | 1469 | 0.140 |
Why?
|
Dacarbazine | 2 | 2016 | 488 | 0.140 |
Why?
|
Cervical Vertebrae | 1 | 2017 | 217 | 0.140 |
Why?
|
Soft Tissue Neoplasms | 1 | 2003 | 909 | 0.140 |
Why?
|
Body Temperature | 2 | 2014 | 163 | 0.140 |
Why?
|
Image-Guided Biopsy | 1 | 2019 | 333 | 0.140 |
Why?
|
Stereotaxic Techniques | 4 | 2004 | 185 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2020 | 463 | 0.130 |
Why?
|
Biopsy | 4 | 2018 | 3483 | 0.130 |
Why?
|
Oncolytic Viruses | 1 | 2018 | 186 | 0.130 |
Why?
|
Software | 4 | 2023 | 1354 | 0.130 |
Why?
|
Photons | 1 | 2019 | 517 | 0.130 |
Why?
|
Endothelin Receptor Antagonists | 1 | 2015 | 25 | 0.130 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2021 | 1697 | 0.130 |
Why?
|
Verbal Learning | 1 | 2015 | 84 | 0.130 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2021 | 858 | 0.130 |
Why?
|
Oncolytic Virotherapy | 1 | 2018 | 257 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2017 | 293 | 0.120 |
Why?
|
Neoplasm Grading | 5 | 2020 | 1807 | 0.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2017 | 2123 | 0.120 |
Why?
|
Preoperative Care | 3 | 2016 | 1564 | 0.120 |
Why?
|
Cranial Irradiation | 3 | 2006 | 323 | 0.120 |
Why?
|
Lung Neoplasms | 5 | 2023 | 11816 | 0.120 |
Why?
|
Electric Stimulation | 5 | 2016 | 442 | 0.120 |
Why?
|
Antibodies, Monoclonal, Humanized | 4 | 2020 | 3361 | 0.120 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2020 | 501 | 0.120 |
Why?
|
Receptor, EphB4 | 1 | 2014 | 27 | 0.120 |
Why?
|
Infrared Rays | 1 | 2014 | 58 | 0.120 |
Why?
|
Spinal Cord Compression | 1 | 2015 | 159 | 0.120 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 1425 | 0.110 |
Why?
|
Patient Safety | 1 | 2019 | 675 | 0.110 |
Why?
|
Prognosis | 10 | 2023 | 22228 | 0.110 |
Why?
|
Karnofsky Performance Status | 5 | 2015 | 176 | 0.110 |
Why?
|
Venereal Tumors, Veterinary | 1 | 2012 | 10 | 0.110 |
Why?
|
Phenytoin | 1 | 2013 | 73 | 0.110 |
Why?
|
Meningitis | 2 | 2013 | 114 | 0.110 |
Why?
|
Adenoviridae | 1 | 2018 | 1455 | 0.100 |
Why?
|
STAT3 Transcription Factor | 2 | 2009 | 1138 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 1657 | 0.100 |
Why?
|
Coronavirus Infections | 1 | 2020 | 654 | 0.100 |
Why?
|
Quality Improvement | 1 | 2019 | 919 | 0.100 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 723 | 0.100 |
Why?
|
Intraoperative Complications | 1 | 2014 | 308 | 0.100 |
Why?
|
Memory | 1 | 2015 | 436 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5465 | 0.100 |
Why?
|
Administration, Cutaneous | 1 | 2011 | 144 | 0.100 |
Why?
|
Pruritus | 1 | 2011 | 88 | 0.100 |
Why?
|
Child | 14 | 2019 | 30092 | 0.100 |
Why?
|
Catheterization | 1 | 2013 | 430 | 0.100 |
Why?
|
Propensity Score | 1 | 2014 | 784 | 0.090 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2010 | 45 | 0.090 |
Why?
|
Catheters, Indwelling | 1 | 2013 | 382 | 0.090 |
Why?
|
Skin | 2 | 2007 | 1283 | 0.090 |
Why?
|
Protons | 1 | 2003 | 476 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 4 | 2015 | 6265 | 0.090 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 271 | 0.090 |
Why?
|
Intracranial Hemorrhages | 1 | 2011 | 121 | 0.090 |
Why?
|
Necrosis | 3 | 2020 | 597 | 0.090 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2010 | 28 | 0.090 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2010 | 122 | 0.090 |
Why?
|
Chemoradiotherapy | 2 | 2016 | 1991 | 0.090 |
Why?
|
Angiomatosis | 1 | 2009 | 27 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2015 | 637 | 0.090 |
Why?
|
Esophageal Neoplasms | 1 | 2003 | 3241 | 0.090 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1890 | 0.090 |
Why?
|
Hot Temperature | 1 | 2010 | 283 | 0.090 |
Why?
|
Survival Analysis | 7 | 2010 | 9320 | 0.090 |
Why?
|
Tumor Burden | 3 | 2024 | 2018 | 0.080 |
Why?
|
Anticonvulsants | 1 | 2013 | 441 | 0.080 |
Why?
|
Brain Diseases | 2 | 2010 | 404 | 0.080 |
Why?
|
Pyrroles | 1 | 2013 | 594 | 0.080 |
Why?
|
Sensitivity and Specificity | 5 | 2014 | 5121 | 0.080 |
Why?
|
Positron-Emission Tomography | 3 | 2014 | 2210 | 0.080 |
Why?
|
Tomography, Emission-Computed | 1 | 2010 | 324 | 0.080 |
Why?
|
Neurilemmoma | 1 | 2009 | 128 | 0.080 |
Why?
|
Perioperative Care | 1 | 2013 | 459 | 0.080 |
Why?
|
Chemokine CXCL12 | 1 | 2009 | 132 | 0.080 |
Why?
|
Radiotherapy, Conformal | 2 | 2004 | 908 | 0.080 |
Why?
|
Cerebral Cortex | 2 | 2010 | 627 | 0.080 |
Why?
|
Tyrphostins | 1 | 2008 | 108 | 0.080 |
Why?
|
Histamine H1 Antagonists | 1 | 2008 | 25 | 0.080 |
Why?
|
Infant | 8 | 2019 | 13756 | 0.080 |
Why?
|
Pia Mater | 1 | 2008 | 15 | 0.080 |
Why?
|
Arachnoid | 1 | 2008 | 14 | 0.080 |
Why?
|
Disease Progression | 5 | 2019 | 6888 | 0.080 |
Why?
|
Models, Theoretical | 1 | 2012 | 795 | 0.080 |
Why?
|
Child, Preschool | 8 | 2019 | 16732 | 0.080 |
Why?
|
Neoplasm Seeding | 1 | 2008 | 66 | 0.080 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 3693 | 0.080 |
Why?
|
Evoked Potentials, Motor | 3 | 2014 | 59 | 0.080 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2011 | 2428 | 0.080 |
Why?
|
Topotecan | 1 | 2008 | 241 | 0.070 |
Why?
|
Logistic Models | 5 | 2016 | 3519 | 0.070 |
Why?
|
Indoles | 1 | 2013 | 1021 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2009 | 717 | 0.070 |
Why?
|
Nanoparticles | 1 | 2012 | 579 | 0.070 |
Why?
|
Treatment Failure | 3 | 2024 | 1431 | 0.070 |
Why?
|
Patient Selection | 3 | 2020 | 2115 | 0.070 |
Why?
|
Antineoplastic Agents | 4 | 2013 | 14501 | 0.070 |
Why?
|
Analysis of Variance | 4 | 2015 | 2327 | 0.070 |
Why?
|
Neurologic Examination | 2 | 2009 | 251 | 0.070 |
Why?
|
Seizures | 1 | 2013 | 999 | 0.070 |
Why?
|
Herpes Zoster Vaccine | 1 | 2006 | 12 | 0.070 |
Why?
|
Reproducibility of Results | 6 | 2015 | 6192 | 0.070 |
Why?
|
Leukocytes, Mononuclear | 1 | 2009 | 707 | 0.070 |
Why?
|
Breast Neoplasms | 4 | 2017 | 16050 | 0.070 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2008 | 688 | 0.070 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2017 | 1904 | 0.070 |
Why?
|
Genomics | 1 | 2017 | 2818 | 0.070 |
Why?
|
Incidence | 4 | 2013 | 5887 | 0.070 |
Why?
|
Germinoma | 1 | 2006 | 85 | 0.070 |
Why?
|
Hypothalamic Neoplasms | 1 | 2006 | 21 | 0.070 |
Why?
|
Solutions | 1 | 2006 | 107 | 0.070 |
Why?
|
Liver Neoplasms | 1 | 2023 | 4773 | 0.070 |
Why?
|
Lasers | 2 | 2020 | 217 | 0.070 |
Why?
|
Gels | 1 | 2006 | 110 | 0.070 |
Why?
|
Sulfonamides | 1 | 2015 | 1896 | 0.070 |
Why?
|
Spider Bites | 1 | 2005 | 2 | 0.070 |
Why?
|
Spider Venoms | 1 | 2005 | 10 | 0.070 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 345 | 0.070 |
Why?
|
Hydroxides | 1 | 2005 | 8 | 0.070 |
Why?
|
Periodic Acid-Schiff Reaction | 1 | 2005 | 8 | 0.070 |
Why?
|
Clinical Trials as Topic | 3 | 2006 | 3836 | 0.060 |
Why?
|
Potassium Compounds | 1 | 2005 | 13 | 0.060 |
Why?
|
Hypersensitivity | 1 | 2008 | 226 | 0.060 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 3518 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2002 | 4775 | 0.060 |
Why?
|
Judaism | 1 | 2004 | 1 | 0.060 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2005 | 112 | 0.060 |
Why?
|
Hyperbaric Oxygenation | 1 | 2005 | 51 | 0.060 |
Why?
|
Skin Ulcer | 1 | 2005 | 76 | 0.060 |
Why?
|
Administration, Topical | 2 | 2003 | 265 | 0.060 |
Why?
|
Preoperative Period | 2 | 2017 | 345 | 0.060 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2004 | 9 | 0.060 |
Why?
|
Osteosarcoma | 1 | 2002 | 947 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2014 | 3930 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2023 | 5113 | 0.060 |
Why?
|
Diagnostic Techniques, Neurological | 1 | 2004 | 11 | 0.060 |
Why?
|
Leg | 1 | 2006 | 232 | 0.060 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2008 | 529 | 0.060 |
Why?
|
Neurocutaneous Syndromes | 1 | 2004 | 19 | 0.060 |
Why?
|
Religion and Medicine | 1 | 2004 | 48 | 0.060 |
Why?
|
Quality of Life | 2 | 2015 | 4719 | 0.060 |
Why?
|
Age Factors | 4 | 2015 | 5490 | 0.060 |
Why?
|
Bayes Theorem | 2 | 2023 | 1057 | 0.060 |
Why?
|
Radiopharmaceuticals | 1 | 2010 | 1335 | 0.060 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 553 | 0.060 |
Why?
|
Risk Factors | 7 | 2021 | 18229 | 0.060 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 5936 | 0.060 |
Why?
|
Nervous System Diseases | 3 | 2017 | 525 | 0.060 |
Why?
|
Fungi | 1 | 2005 | 144 | 0.060 |
Why?
|
Pemphigus | 1 | 2003 | 8 | 0.060 |
Why?
|
Back | 1 | 2003 | 45 | 0.060 |
Why?
|
Meta-Analysis as Topic | 1 | 2005 | 282 | 0.060 |
Why?
|
Fusobacterium Infections | 1 | 2003 | 31 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 5030 | 0.060 |
Why?
|
Genome, Human | 1 | 2011 | 1896 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 2339 | 0.050 |
Why?
|
Brain Abscess | 1 | 2003 | 67 | 0.050 |
Why?
|
Laminectomy | 1 | 2003 | 52 | 0.050 |
Why?
|
Spinal Cord | 1 | 2006 | 701 | 0.050 |
Why?
|
Arm | 1 | 2003 | 148 | 0.050 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2003 | 60 | 0.050 |
Why?
|
Pyrimidines | 1 | 2015 | 3603 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2009 | 1569 | 0.050 |
Why?
|
Disease-Free Survival | 4 | 2017 | 10092 | 0.050 |
Why?
|
Leukemia | 1 | 2011 | 1653 | 0.050 |
Why?
|
Immunotherapy | 2 | 2023 | 3480 | 0.050 |
Why?
|
Postoperative Period | 2 | 2018 | 672 | 0.050 |
Why?
|
Models, Biological | 1 | 2011 | 3254 | 0.050 |
Why?
|
Angiography | 1 | 2023 | 361 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2017 | 2273 | 0.050 |
Why?
|
Severity of Illness Index | 3 | 2010 | 4460 | 0.050 |
Why?
|
Pyridines | 1 | 2008 | 1289 | 0.050 |
Why?
|
Carcinoma, Endometrioid | 1 | 2004 | 325 | 0.050 |
Why?
|
Receptor, Adenosine A2A | 1 | 2020 | 27 | 0.050 |
Why?
|
Administration, Oral | 1 | 2005 | 1581 | 0.050 |
Why?
|
Cerebellum | 1 | 2004 | 467 | 0.050 |
Why?
|
Apyrase | 1 | 2020 | 44 | 0.050 |
Why?
|
ROC Curve | 2 | 2014 | 1224 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2011 | 5704 | 0.050 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2004 | 441 | 0.050 |
Why?
|
5'-Nucleotidase | 1 | 2020 | 65 | 0.050 |
Why?
|
Lumbar Vertebrae | 1 | 2001 | 250 | 0.040 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2016 | 595 | 0.040 |
Why?
|
Carcinoma, Papillary | 1 | 2004 | 590 | 0.040 |
Why?
|
Cadherins | 1 | 2003 | 675 | 0.040 |
Why?
|
Asthma | 1 | 2008 | 904 | 0.040 |
Why?
|
Secondary Prevention | 1 | 2002 | 340 | 0.040 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2005 | 620 | 0.040 |
Why?
|
Leukapheresis | 1 | 2020 | 162 | 0.040 |
Why?
|
Dogs | 2 | 2012 | 1174 | 0.040 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 14849 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 4639 | 0.040 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2004 | 494 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2015 | 1354 | 0.040 |
Why?
|
Mutation | 2 | 2024 | 15577 | 0.040 |
Why?
|
Central Nervous System Neoplasms | 1 | 2004 | 547 | 0.040 |
Why?
|
Chondrosarcoma | 1 | 2001 | 217 | 0.040 |
Why?
|
Lymphocyte Depletion | 1 | 2020 | 290 | 0.040 |
Why?
|
Cell Movement | 1 | 2007 | 2498 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2020 | 2980 | 0.040 |
Why?
|
Image Enhancement | 1 | 2003 | 568 | 0.040 |
Why?
|
Animals | 7 | 2020 | 60938 | 0.040 |
Why?
|
Empathy | 1 | 2020 | 107 | 0.040 |
Why?
|
Family Health | 2 | 2011 | 332 | 0.040 |
Why?
|
Triage | 1 | 2020 | 256 | 0.040 |
Why?
|
Ipilimumab | 1 | 2023 | 749 | 0.040 |
Why?
|
Factor Analysis, Statistical | 2 | 2010 | 352 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2003 | 537 | 0.040 |
Why?
|
Ultrasonography, Interventional | 1 | 2001 | 451 | 0.040 |
Why?
|
Medical History Taking | 1 | 1999 | 181 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2013 | 4884 | 0.040 |
Why?
|
Texas | 3 | 2020 | 6454 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2021 | 549 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 2018 | 163 | 0.040 |
Why?
|
Odds Ratio | 2 | 2015 | 2361 | 0.040 |
Why?
|
Phantoms, Imaging | 1 | 2003 | 1314 | 0.040 |
Why?
|
Cranial Nerve Injuries | 1 | 2017 | 9 | 0.040 |
Why?
|
Surveys and Questionnaires | 1 | 2010 | 5913 | 0.040 |
Why?
|
Craniocerebral Trauma | 1 | 1999 | 135 | 0.040 |
Why?
|
Consensus | 1 | 2021 | 1074 | 0.040 |
Why?
|
Ventriculostomy | 1 | 2017 | 39 | 0.040 |
Why?
|
Growth Disorders | 1 | 1999 | 218 | 0.040 |
Why?
|
Mice, Nude | 2 | 2015 | 4343 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2020 | 481 | 0.040 |
Why?
|
Morbidity | 1 | 2018 | 413 | 0.040 |
Why?
|
Gait Disorders, Neurologic | 1 | 2017 | 54 | 0.040 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 2017 | 76 | 0.040 |
Why?
|
Speech Disorders | 1 | 2017 | 91 | 0.040 |
Why?
|
Cohort Studies | 3 | 2017 | 9476 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2017 | 418 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2010 | 1082 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 1130 | 0.030 |
Why?
|
Risk Assessment | 2 | 2021 | 7162 | 0.030 |
Why?
|
Semantics | 1 | 2015 | 60 | 0.030 |
Why?
|
Machine Learning | 1 | 2019 | 356 | 0.030 |
Why?
|
Healthy Volunteers | 1 | 2016 | 190 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2016 | 2362 | 0.030 |
Why?
|
Neoplasm Staging | 4 | 2014 | 13879 | 0.030 |
Why?
|
Time Factors | 4 | 2017 | 13251 | 0.030 |
Why?
|
Antigens, CD | 1 | 2020 | 1409 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2008 | 3955 | 0.030 |
Why?
|
Radiography | 2 | 2015 | 1942 | 0.030 |
Why?
|
Metastasectomy | 1 | 2017 | 208 | 0.030 |
Why?
|
Recurrence | 1 | 2003 | 4873 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2020 | 1978 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2015 | 264 | 0.030 |
Why?
|
Betacoronavirus | 1 | 2020 | 532 | 0.030 |
Why?
|
Research Design | 1 | 2002 | 1598 | 0.030 |
Why?
|
Intraoperative Care | 1 | 2016 | 270 | 0.030 |
Why?
|
Mental Recall | 1 | 2015 | 178 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2002 | 1260 | 0.030 |
Why?
|
Area Under Curve | 1 | 2016 | 722 | 0.030 |
Why?
|
Heterocyclic Compounds, 1-Ring | 1 | 2014 | 5 | 0.030 |
Why?
|
Psychometrics | 2 | 2010 | 960 | 0.030 |
Why?
|
Brain Stem | 1 | 2015 | 177 | 0.030 |
Why?
|
Carbocyanines | 1 | 2014 | 40 | 0.030 |
Why?
|
Autoradiography | 1 | 2014 | 133 | 0.030 |
Why?
|
Affect | 1 | 2015 | 290 | 0.030 |
Why?
|
Surface Plasmon Resonance | 1 | 2014 | 103 | 0.030 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2020 | 1069 | 0.030 |
Why?
|
Breast Neoplasms, Male | 1 | 2015 | 233 | 0.030 |
Why?
|
Fluorescence | 1 | 2014 | 202 | 0.030 |
Why?
|
Executive Function | 1 | 2014 | 161 | 0.030 |
Why?
|
Macrophages | 1 | 2020 | 1372 | 0.030 |
Why?
|
Pilot Projects | 1 | 2020 | 2857 | 0.030 |
Why?
|
Postoperative Care | 1 | 2017 | 751 | 0.030 |
Why?
|
Luciferases | 1 | 2014 | 454 | 0.030 |
Why?
|
Attention | 1 | 2014 | 288 | 0.030 |
Why?
|
Creatine | 1 | 2002 | 62 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2015 | 920 | 0.030 |
Why?
|
Choline | 1 | 2002 | 76 | 0.030 |
Why?
|
Decision Making | 1 | 2020 | 1341 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2014 | 907 | 0.030 |
Why?
|
Cerebral Angiography | 1 | 2002 | 142 | 0.030 |
Why?
|
Finite Element Analysis | 1 | 2011 | 60 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2020 | 5663 | 0.030 |
Why?
|
Lod Score | 1 | 2011 | 162 | 0.020 |
Why?
|
Therapy, Computer-Assisted | 1 | 2011 | 62 | 0.020 |
Why?
|
Mice | 3 | 2020 | 35283 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2014 | 1079 | 0.020 |
Why?
|
Pain Measurement | 1 | 2015 | 995 | 0.020 |
Why?
|
Pandemics | 1 | 2020 | 1625 | 0.020 |
Why?
|
Cell Division | 1 | 2015 | 2554 | 0.020 |
Why?
|
Motor Skills Disorders | 1 | 2010 | 19 | 0.020 |
Why?
|
Learning | 1 | 2014 | 418 | 0.020 |
Why?
|
Lactic Acid | 1 | 2002 | 310 | 0.020 |
Why?
|
Biophysical Phenomena | 1 | 2010 | 113 | 0.020 |
Why?
|
Kinetics | 1 | 2014 | 2098 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 4906 | 0.020 |
Why?
|
Electrophysiological Phenomena | 1 | 2010 | 77 | 0.020 |
Why?
|
Serum Albumin | 1 | 2011 | 249 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2011 | 474 | 0.020 |
Why?
|
Temperature | 1 | 2011 | 522 | 0.020 |
Why?
|
Thermodynamics | 1 | 2010 | 201 | 0.020 |
Why?
|
Nerve Fibers | 1 | 2010 | 115 | 0.020 |
Why?
|
Corpus Callosum | 1 | 2010 | 141 | 0.020 |
Why?
|
Frontal Lobe | 1 | 2010 | 188 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2011 | 322 | 0.020 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2011 | 314 | 0.020 |
Why?
|
Down-Regulation | 1 | 2015 | 2113 | 0.020 |
Why?
|
Transcription Factors | 1 | 2024 | 5357 | 0.020 |
Why?
|
Sickness Impact Profile | 1 | 2010 | 139 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 7154 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2002 | 487 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2015 | 1076 | 0.020 |
Why?
|
Sex Factors | 1 | 2014 | 2215 | 0.020 |
Why?
|
Anesthesia, General | 1 | 2010 | 238 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2014 | 871 | 0.020 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 102 | 0.020 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2008 | 83 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2010 | 241 | 0.020 |
Why?
|
Pons | 1 | 2008 | 49 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2011 | 1497 | 0.020 |
Why?
|
Fas Ligand Protein | 1 | 2008 | 153 | 0.020 |
Why?
|
Peptides | 1 | 2014 | 1503 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2004 | 4730 | 0.020 |
Why?
|
Databases, Factual | 1 | 2015 | 2315 | 0.020 |
Why?
|
Epidural Space | 1 | 2007 | 43 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2015 | 4383 | 0.020 |
Why?
|
Cell Line | 1 | 2015 | 5126 | 0.020 |
Why?
|
Pedigree | 1 | 2011 | 1930 | 0.020 |
Why?
|
CD3 Complex | 1 | 2008 | 316 | 0.020 |
Why?
|
fas Receptor | 1 | 2008 | 193 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2008 | 6241 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2005 | 7901 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2009 | 592 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2008 | 525 | 0.020 |
Why?
|
Computer Simulation | 1 | 2011 | 1575 | 0.020 |
Why?
|
Chest Pain | 1 | 2007 | 171 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2013 | 1787 | 0.020 |
Why?
|
Medical Records | 1 | 2007 | 425 | 0.020 |
Why?
|
Electroencephalography | 1 | 2010 | 936 | 0.020 |
Why?
|
Acute Disease | 1 | 2011 | 2469 | 0.020 |
Why?
|
Biomarkers, Tumor | 2 | 2019 | 10623 | 0.020 |
Why?
|
Radiotherapy, High-Energy | 1 | 2006 | 300 | 0.020 |
Why?
|
Resins, Synthetic | 1 | 2004 | 3 | 0.020 |
Why?
|
Patch Tests | 1 | 2004 | 7 | 0.020 |
Why?
|
Neuroanatomy | 1 | 2004 | 14 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2009 | 1059 | 0.010 |
Why?
|
Models, Statistical | 1 | 2010 | 1205 | 0.010 |
Why?
|
Peptostreptococcus | 1 | 2003 | 7 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2008 | 1162 | 0.010 |
Why?
|
Bacteroides Infections | 1 | 2003 | 10 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2008 | 1263 | 0.010 |
Why?
|
Desmoglein 1 | 1 | 2003 | 2 | 0.010 |
Why?
|
SEER Program | 1 | 2007 | 1012 | 0.010 |
Why?
|
Mupirocin | 1 | 2003 | 25 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 1253 | 0.010 |
Why?
|
Neoplasms | 1 | 2010 | 15695 | 0.010 |
Why?
|
Genotype | 1 | 2011 | 4166 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2004 | 326 | 0.010 |
Why?
|
Immobilization | 1 | 2003 | 95 | 0.010 |
Why?
|
Maternal-Fetal Exchange | 1 | 2003 | 88 | 0.010 |
Why?
|
Radiotherapy | 1 | 2010 | 1852 | 0.010 |
Why?
|
Sensation Disorders | 1 | 2002 | 36 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2004 | 769 | 0.010 |
Why?
|
Allergens | 1 | 2004 | 251 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2007 | 596 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2002 | 427 | 0.010 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2003 | 160 | 0.010 |
Why?
|
Methods | 1 | 2001 | 190 | 0.010 |
Why?
|
Up-Regulation | 1 | 2008 | 2480 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2003 | 389 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2008 | 3071 | 0.010 |
Why?
|
Respiration | 1 | 2003 | 452 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 3089 | 0.010 |
Why?
|
Particle Accelerators | 1 | 2003 | 361 | 0.010 |
Why?
|
Regression Analysis | 1 | 2004 | 1569 | 0.010 |
Why?
|
Phosphorylation | 1 | 2008 | 4885 | 0.010 |
Why?
|
Movement | 1 | 2003 | 564 | 0.010 |
Why?
|
Equipment Design | 1 | 2003 | 1231 | 0.010 |
Why?
|
Clostridium Infections | 1 | 2003 | 256 | 0.010 |
Why?
|
Autoantibodies | 1 | 2003 | 589 | 0.010 |
Why?
|
Models, Animal | 1 | 2002 | 692 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2002 | 679 | 0.010 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2002 | 611 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2003 | 1395 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2003 | 949 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2003 | 2344 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2004 | 2095 | 0.010 |
Why?
|
United States | 1 | 2011 | 16302 | 0.010 |
Why?
|
Palliative Care | 1 | 2005 | 2130 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 16258 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2003 | 7702 | 0.010 |
Why?
|
Pregnancy | 1 | 2003 | 7819 | 0.010 |
Why?
|
Signal Transduction | 1 | 2008 | 12135 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2003 | 8534 | 0.010 |
Why?
|